Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in China / NCT07297641
Recruiting Observational

Intravascular Imaging-Guided Versus Angiography- Guided PCI in Patients With DES-ISR

NCT07297641 · tracked via the Priya Life Science China tracker
Sponsor
Nanjing First Hospital, Nanjing Medical University
Phase
Observational
Started
2026-01-01
Last updated
2025-12-22

Condition(s) studied

PCIIn-stent RestenosisIntravascular Imaging Device

Investigational drug(s) / intervention(s)

percutaneous coronary intervention

percutaneous coronary intervention: Percutaneous Coronary Intervention for ISR

Study summary

This study aimed to compare the clinical and angiographic outcomes of patients with DES-ISR who underwent repeat PCI with intravascular imaging or angiographic guidance.

Eligibility

Sex
ALL
Min age
18 Years
Max age
80 Years
Healthy volunteers
No
Inclusion Criteria: (1) Patients with DES-ISR lesions; (2) Life expectancy of at least 1 year; (3) DES-ISR lesions occurring for the first time in native coronary arteries and suitable for re-PCI based on angiographic findings. Exclusion Criteria: (1) Bare-metal stent in-stent restenosis (BMS-ISR). (2) Non-DES-ISR lesions. (3) Incomplete clinical and angiographic data. (4) Poor quality of IVUS or angiographic images. (5) Recurrent DES-ISR. (6) Optical coherence tomography (OCT) guidance.

Primary outcome measure(s)

  • MACE — 3-year
    Major adverse cardiovascular events following PCI

Trial sites (1)

FacilityCityRegionStatus
Nanjing First Hospital Nanjing Jiangsu Recruiting

More Nanjing First Hospital, Nanjing Medical University trials in China

Coronary and Myocardial Evaluation by Cardiac CT for Acute Myocardial Infarction Recruiting
The Study of Postoperative Delirium and Glymphatic System Function in Cardiac Surgery Active, not recruiting
The Effect of Bupivacaine Liposome Preemptive Analgesia on Postoperative Pain and Delirium in Elderly Patients Undergoing Hip Fracture Surgery Starting soon
Characteristics of Papez Loop Neural Network in T2DM （Type 2 Diabetes Mellitus） Recruiting
Effects of Tirzepatide on Gut Microbiota and Gastrointestinal Function After Drug Withdrawal in Obese Patients Starting soon

Other trials for the same condition

Anti-inflammatory Therapy for Recurrent In-stent Restenosis Recruiting
VAP-Measured Lipid Subfractions and In-Stent Restenosis After PCI Active, not recruiting
Impact of Procedural Factors on Drug-Coated Balloon Outcomes in Coronary Artery Disease Recruiting
Intravascular Ultrasound guidaNce versuS angIoGrapHy Guidance in Patients With ST-segment Elevation Myocardial Infarction Starting soon
Super High-pressure Balloon Versus Intravascular Lithotripsy to Prepare Severely Calcified Coronary Lesions Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07297641 on ClinicalTrials.gov ↗ ← All trials in China